GUSTAVO CARDOSO GUIMARÃES...GUSTAVO CARDOSO GUIMARÃES DIRETOR GERAL DOS DEPARTAMENTOS DE CIRURGIA...
Transcript of GUSTAVO CARDOSO GUIMARÃES...GUSTAVO CARDOSO GUIMARÃES DIRETOR GERAL DOS DEPARTAMENTOS DE CIRURGIA...
GUSTAVO CARDOSO GUIMARÃES
DIRETOR GERAL DOS DEPARTAMENTOS DE CIRURGIA ONCOLÓGICA
BP A BENEFICENCIA PORTUGUESA DE SÃO PAULO
DIRETOR – IUCR DR GUSTAVO GUIMARAES
INSTITUTO DE UROLOGIA, ONCOLOGIA E CIRURGIA ROBOTICA
TRATAMENTO DA RECIDIVA LOCAL APÓS TERAPIA RADICAL
HIFU - BEST TREATMENT AND BEST OUTCOMES
Cancer 2008, 112; 307-14
HIFU - BEST TREATMENT AND BEST OUTCOMES
HIFU - BEST TREATMENT AND BEST OUTCOMES
HIFU - BEST TREATMENT AND BEST OUTCOMES
HIFU - BEST TREATMENT AND BEST OUTCOMES
Cancer 2008, 112; 307-14
HIFU - BEST TREATMENT AND BEST OUTCOMES
• 30 a 60% - Relapse after Radiotherapy
Kuban DA, et al. Int. J. Radiat. Oncol. Biol. Phys. 2003; 57: 915–28.
Lee WR, et al. A. J. Clin. Oncol. 1997; 15: 230–8.
Agarwal PK, et al. Cancer. 2008 Jan 15;112(2):307-14.
473 pts, D’Amico
QUAIS AS OPÇÕES DE TRATAMENTO APÓS
FALHA DA RADIOTERAPIA ??
Câncer de Próstata - Falha Pós Radioterapia
(Poucos estudos randomizados controlados)
• Observação
• Hormonioterapia
• Prostatectomia de Resgate
• Braquiterapia de Resgate
• Crioterapia de Resgate
• HIFU de Resgate
HIFU CAN BE USED AS:
Whole gland, hemi and zonal ablation and true focal therapy
• PRIMARY TREATMENT
• SALVAGE TREATMENT
• PALLIATIVE AND ADJUVANT (Investigational)
HIFU - BEST TREATMENT AND BEST OUTCOMES
SALVAGE HIFU
HIFU - BEST TREATMENT AND BEST OUTCOMES
SALVAGE HIFU
HIFU - BEST TREATMENT AND BEST OUTCOMES
HIFU - BEST TREATMENT AND BEST OUTCOMES
Cancer 2008, 112; 307-14
HIFU - BEST TREATMENT AND BEST OUTCOMES
Cancer 2014, 120; 507-12 2/366 (0,54%)
6275 pts submitted to radical therapy
839 pts with biochemical relapse (13,4%)
HIFU - BEST TREATMENT AND BEST OUTCOMES
HIFU - BEST TREATMENT AND BEST OUTCOMES
2018
HIFU - BEST TREATMENT AND BEST OUTCOMES
2019
Candidate for Salvage local therapy: (whole gland)
(Salvage FT – investigational only in clinical trial)
• Original clinical stage T1-T2, Nx or N0
• Life expectancy >10 y
• PSA now <10 ng/mL
• Exclude metastatic disease (MRI, PET-Ct, etc)
HIFU - BEST TREATMENT AND BEST OUTCOMES
Multicentric oncologic outcomes of salvage HIFU for local failure after external beam radiotherapy: 7 years biochemical survival of 929 patients
S. Crouzet, Lyon (FR)
• Mean follow-up: 66 ± 35 months
No Pre Treatment Hormone
Therapy
Pre Treatment Hormone Therapy
PSA ≤ 4 PSA:4-10 PSA>10 PSA ≤ 4 PSA:4-10 PSA>10
5-year
BDFS
78% 59% 49% 49% 38% 32%
6-year
BDFS
67% 56% 43% 49% 34% 26%
7-year
BDFS
59% 56% 31% 49% 34% 17%
HIFU DE RESGATE É EFETIVO, COM RESULTADOS
DURÁVEIS E REPRODUTÍVEIS
929 salvage patients
7 year follow-up
HIFU - BEST TREATMENT AND BEST OUTCOMES
• 418 pts
• Retrospective Study – 1995 – 2009
• Two diferente HIFU parameters
• bFFS rate at 5 years was 49%
• CSS at 7 years was 82%
HIFU - BEST TREATMENT AND BEST OUTCOMES
• Continence (no pads+ grade 1)
Overall - 78,7%
Post-RT parameters – 81,2%
• Rectal Fistula – 0,6%
Câncer de Próstata - Falha Pós Radioterapia
7 anos
OS - 72%CSS - 82%MFS – 81%
Câncer de Próstata - Falha Pós Radioterapia
Resultado - Falha bioquímica
PSA <4Não usar ADT
Câncer de Próstata - Falha Pós Radioterapia
Resultado – Falha bioquímica
Baixo risco = intermediário>Gleason --> pior result.
Câncer de Próstata - Falha Pós Radioterapia
Sobrevida livre de terapia de resgate
HIFU - BEST TREATMENT AND BEST OUTCOMES
• 418 pts
• Retrospective Study – 1995 – 2009
• bFFS rate at 5 years was 49%
• CSS at 7 years was 82%
• 404 pts
• Colaborative /retropective study
• bFFS rate at 10 years was 37%
• CSS at 10 years was 83%
Eur Urol, 2011. 60: 205
Câncer de Próstata - Falha Pós Radioterapia
150 pcts
Seguimento mediano 35 meses (22-52)
BDFS –(3 anos) 48%
dDFS grupo risco %(2,7%) Baixo – 100%(39,3%) Interm. – 61%(41,3%) Alto - 32%
HIFU - BEST TREATMENT AND BEST OUTCOMES
Potência
(26pcts dados disponíveis >18 meses)
11,5% Potente
3,8% - Potente sem droga
7,7% - Potente com droga
11,5% - Impotente
76,9% - Impotente prévio
RESULTADOS
(Seguimento mediano 36 meses)
56 (16,7%) HIFU de resgate
Continência
(35 pcts dados disponíveis > 18 meses)
74,3% - Continente (até 1 forro)
8,6% - Incontinente leve a moderado
5,7% - Incontinente grave
8,6% - Incontinente prévio
2,9% - Bricker (1 pct – progressão tumoral)
HIFU - BEST TREATMENT AND BEST OUTCOMESRESULTADOS
Vivo sem doença – 46,4%
Vivo com doença – 26,8%
Morte pelo Câncer – 1,8%
Perdido de vista – 25,0%
TRATAMENTO APÓS FALHA
RE-HIFU 4,8% (2 CASOS)
HT 52,4%
QUIMIO 14,3%
OBSERV 28,6%
56 (16,7%) HIFU de resgate
CONCLUSIONS
Candidatos para HIFU de resgate - whole gland
(Salvage FT – investigational)
HIFU - BEST TREATMENT AND BEST OUTCOMES